Optical tweezers

IMS Developing Japan's First "Cold (Neutral) Atom" Quantum Computers: New Collaboration with 10 Industry Partners toward Commercialization

Retrieved on: 
Tuesday, March 12, 2024
Temperature, Natural science, Innovation, Growth, Commercialization, Development finance institution, Professor, Business, Internet, Research, Electronics, Artificial intelligence, University, Software, Computer, Quantum, IMS, Architecture, NEC, University of California, Hitachi, Optical tweezers, Fujitsu, Bangladesh Technical Education Board, Silicon, Microscope

The launch of the PF was made possible by collaboration with 10 industry partners, including companies and financial institutions.

Key Points: 
  • The launch of the PF was made possible by collaboration with 10 industry partners, including companies and financial institutions.
  • It plans to launch a start-up company by the end of its FY2024 and begin the development of "cold (neutral) atom" quantum computers.
  • The Ohmori group at the IMS is leading the world in developing the cold (neutral) atom quantum computers.
  • By taking advantage of these technical advances and core competencies of the Ohmori group, the IMS will accelerate the development and commercialization of quantum computers in collaboration with its industry partners.

IMS Developing Japan's First "Cold (Neutral) Atom" Quantum Computers: New Collaboration with 10 Industry Partners toward Commercialization

Retrieved on: 
Tuesday, March 12, 2024
Temperature, Natural science, Innovation, Growth, Commercialization, Development finance institution, Professor, Business, Internet, Research, Electronics, Artificial intelligence, University, Software, Computer, Quantum, IMS, Architecture, NEC, University of California, Hitachi, Optical tweezers, Fujitsu, Bangladesh Technical Education Board, Silicon, Microscope

The launch of the PF was made possible by collaboration with 10 industry partners, including companies and financial institutions.

Key Points: 
  • The launch of the PF was made possible by collaboration with 10 industry partners, including companies and financial institutions.
  • It plans to launch a start-up company by the end of its FY2024 and begin the development of "cold (neutral) atom" quantum computers.
  • The Ohmori group at the IMS is leading the world in developing the cold (neutral) atom quantum computers.
  • By taking advantage of these technical advances and core competencies of the Ohmori group, the IMS will accelerate the development and commercialization of quantum computers in collaboration with its industry partners.

LUMICKS Unveils Groundbreaking New C-Trap® Product at Biophysical Society Annual Meeting

Retrieved on: 
Tuesday, February 22, 2022
Molecule, DSM, Health, Protein folding, Microfluidics, Optical tweezers, General manager, STED, Biology, Workflow, Orbitrap, TIRF, Science, DNA-binding protein, C Traps and Pitfalls, Research, Dymo Corporation, IRM, Microscope

Jos Maas, General Manager of LUMICKS' Dynamic Single Molecule (DSM) business unit, states, "We are delighted to expand our portfolio with the introduction of the C-Trap 'Edge'.

Key Points: 
  • Jos Maas, General Manager of LUMICKS' Dynamic Single Molecule (DSM) business unit, states, "We are delighted to expand our portfolio with the introduction of the C-Trap 'Edge'.
  • LUMICKS also announced that it will rebrand its existing flagship C-Trap product line into CTrap'Dymo'.The C-Trap 'Dymo' combines state-of-the-art optical tweezers with microfluidics and confocal or STED microscopy.
  • LUMICKS' C-Trap Optical Tweezers Fluorescence & Label-free Microscopy, allows scientists to analyze complex biological processes in real-time.
  • Similarly, the z-Movi Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells.

LUMICKS Unveils Groundbreaking New C-Trap® Product at Biophysical Society Annual Meeting

Retrieved on: 
Tuesday, February 22, 2022
Molecule, DSM, Health, Protein folding, Microfluidics, Optical tweezers, General manager, STED, Biology, Workflow, Orbitrap, TIRF, Science, DNA-binding protein, C Traps and Pitfalls, Research, Dymo Corporation, IRM, Microscope

AMSTERDAM, Feb. 22, 2022 /PRNewswire/ -- LUMICKS, a leading life science tools company advancing science and improving human health by unlocking the measurement of forces and interactions in biology, today announced that it is introducing a new innovative C-Trap to its portfolio at the 66th Annual Biophysical Society Meeting in San Francisco, California.

Key Points: 
  • Jos Maas, General Manager of LUMICKS' Dynamic Single Molecule (DSM) business unit, states, "We are delighted to expand our portfolio with the introduction of the C-Trap 'Edge'.
  • LUMICKS also announced that it will rebrand its existing flagship C-Trap product line into CTrap'Dymo'.The C-Trap 'Dymo' combines state-of-the-art optical tweezers with microfluidics and confocal or STED microscopy.
  • LUMICKS' C-Trap Optical Tweezers Fluorescence & Label-free Microscopy, allows scientists to analyze complex biological processes in real-time.
  • Similarly, the z-Movi Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells.

LUMICKS Appoints Paul Wheeler to Leadership Team as Chief Commercial Officer to Drive New Business Growth

Retrieved on: 
Tuesday, August 17, 2021
Molecule, Industry, General manager, STED, Chemistry, Vrije Universiteit Amsterdam, Leadership, Pharma, Merck, Research, Physics, Marketing, RND, Biology, Nobel Prize, Head, Optical tweezers, Flow cytometry, EMEA, Associate Director of National Intelligence and Chief Information Officer, Management, Microscope

AMSTERDAM, Aug. 17, 2021 /PRNewswire/ --LUMICKS, a leading next generation life science tools company, is pleased to announce the appointment of Dr. Paul Wheeler to its leadership team, effective July 1, 2021.

Key Points: 
  • AMSTERDAM, Aug. 17, 2021 /PRNewswire/ --LUMICKS, a leading next generation life science tools company, is pleased to announce the appointment of Dr. Paul Wheeler to its leadership team, effective July 1, 2021.
  • In the newly-created position of Chief Commercial Officer, Dr. Wheeler will lead LUMICKS aggressive commercial growth strategy by building a stronger market presence, developing highly-effective sales teams, and focusing on enhanced customer success.
  • Dr. Wheeler brings 20 years of sales experience to LUMICKS, most recently with LUMINEX as Vice President of Flow Cytometry and General Manager EMEA.
  • Dr. Wheeler also brings in-depth experience in managing marketing, RnD and operations teams, as well as expertise in mergers and acquisitions.

LUMICKS Appoints Paul Wheeler to Leadership Team as Chief Commercial Officer to Drive New Business Growth

Retrieved on: 
Tuesday, August 17, 2021
Molecule, Industry, General manager, STED, Chemistry, Vrije Universiteit Amsterdam, Leadership, Pharma, Merck, Research, Physics, Marketing, RND, Biology, Nobel Prize, Head, Optical tweezers, Flow cytometry, EMEA, Associate Director of National Intelligence and Chief Information Officer, Management, Microscope

AMSTERDAM, Aug. 17, 2021 /PRNewswire/ -- LUMICKS, a leading next generation life science tools company, is pleased to announce the appointment of Dr. Paul Wheeler to its leadership team, effective July 1, 2021. In the newly-created position of Chief Commercial Officer, Dr. Wheeler will lead LUMICKS aggressive commercial growth strategy by building a stronger market presence, developing highly-effective sales teams, and focusing on enhanced customer success. 

Key Points: 
  • AMSTERDAM, Aug. 17, 2021 /PRNewswire/ --LUMICKS, a leading next generation life science tools company, is pleased to announce the appointment of Dr. Paul Wheeler to its leadership team, effective July 1, 2021.
  • In the newly-created position of Chief Commercial Officer, Dr. Wheeler will lead LUMICKS aggressive commercial growth strategy by building a stronger market presence, developing highly-effective sales teams, and focusing on enhanced customer success.
  • Dr. Wheeler brings 20 years of sales experience to LUMICKS, most recently with LUMINEX as Vice President of Flow Cytometry and General Manager EMEA.
  • Dr. Wheeler also brings in-depth experience in managing marketing, RnD and operations teams, as well as expertise in mergers and acquisitions.

LUMICKS to return COVID-related relief funding to Dutch and US governments

Retrieved on: 
Tuesday, May 18, 2021
Branches of biology, Physical sciences, Natural sciences, Molecular biology, Laboratory techniques, Cell biology, Microscopy, Medical equipment, Tweezers, Optical tweezers, Fluorescence

We received these funds when we experienced a challenging trading environment due to academic labs cutting back their investment and activities because of the pandemic.

Key Points: 
  • We received these funds when we experienced a challenging trading environment due to academic labs cutting back their investment and activities because of the pandemic.
  • We are fortunate that the strong global interest in life science research has placed LUMICKS in a position of robust recovery.
  • This is achieved by applying and measuring forces around biological interactions, enabling the detailed real-time analysis of underlying biological mechanisms.
  • LUMICKS\' groundbreaking C-Trap Optical Tweezers Fluorescence & Label-free Microscopy, allows scientists for the first time to analyze complex biological processes in real-time.

LUMICKS to return COVID-related relief funding to Dutch and US governments

Retrieved on: 
Tuesday, May 18, 2021
Branches of biology, Physical sciences, Natural sciences, Molecular biology, Laboratory techniques, Cell biology, Microscopy, Medical equipment, Tweezers, Optical tweezers, Fluorescence

We received these funds when we experienced a challenging trading environment due to academic labs cutting back their investment and activities because of the pandemic.

Key Points: 
  • We received these funds when we experienced a challenging trading environment due to academic labs cutting back their investment and activities because of the pandemic.
  • We are fortunate that the strong global interest in life science research has placed LUMICKS in a position of robust recovery.
  • This is achieved by applying and measuring forces around biological interactions, enabling the detailed real-time analysis of underlying biological mechanisms.
  • LUMICKS\' groundbreaking C-Trap Optical Tweezers Fluorescence & Label-free Microscopy, allows scientists for the first time to analyze complex biological processes in real-time.

LUMICKS Raises $93 Million in Series D Financing

Retrieved on: 
Friday, April 16, 2021
Branches of biology, Physical sciences, Natural sciences, Molecular biology, Biophysics, Microscopy, Cell biology, Spectroscopy, Single-molecule experiment, Optical tweezers, Fluorescence microscope, Tweezers

The round was also backed by existing investor Gilde Healthcare and select members of the LUMICKS management team.

Key Points: 
  • The round was also backed by existing investor Gilde Healthcare and select members of the LUMICKS management team.
  • With this fundraising, we believe LUMICKS is well positioned to drive significant growth of our Dynamic Single-Molecule platform and further accelerate the commercial adoption of the industry-changing z-Movi solution.
  • It builds on LUMICKS\' rapid innovation, anchored by its Dynamic Single-Molecule franchise that is expanding access to and use cases for single molecule force measurement.
  • Using LUMICKS\' groundbreaking C-Trap Optical Tweezers Fluorescence Microscopy, scientists are able to analyze complex biological processes in real-time.

LUMICKS Raises $93 Million in Series D Financing

Retrieved on: 
Friday, April 16, 2021
Branches of biology, Physical sciences, Natural sciences, Molecular biology, Biophysics, Microscopy, Cell biology, Spectroscopy, Single-molecule experiment, Optical tweezers, Fluorescence microscope, Tweezers

The round was also backed by existing investor Gilde Healthcare and select members of the LUMICKS management team.

Key Points: 
  • The round was also backed by existing investor Gilde Healthcare and select members of the LUMICKS management team.
  • With this fundraising, we believe LUMICKS is well positioned to drive significant growth of our Dynamic Single-Molecule platform and further accelerate the commercial adoption of the industry-changing z-Movi solution.
  • It builds on LUMICKS\' rapid innovation, anchored by its Dynamic Single-Molecule franchise that is expanding access to and use cases for single molecule force measurement.
  • Using LUMICKS\' groundbreaking C-Trap Optical Tweezers Fluorescence Microscopy, scientists are able to analyze complex biological processes in real-time.